Discovery and development of an aurora kinase inhibitor clinical candidate using an image-based assay for measuring proliferation, apoptosis, and DNA content

Assay and Drug Development Technologies

Volumn 7, Issue 2, 2009, Pages 180-190

  Catalano, Susan M ^a,b   McLaughlin, John ^a   Hitoshi, Yasumichi ^a   Payan, Don ^a  

^a RIGEL PHARMACEUTICALS INC   (United States)

^b Drug Discovery Imaging   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AURORA KINASE; BROXURIDINE; DNA; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE;

APOPTOSIS; ARTICLE; CELL CYCLE G2 PHASE; CELL DIVISION; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; METABOLISM; TUMOR CELL LINE;

APOPTOSIS; BROMODEOXYURIDINE; CELL DIVISION; CELL LINE, TUMOR; CELL PROLIFERATION; DNA; G2 PHASE; HUMANS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES;

EID: 68349092944     PISSN: 1540658X     EISSN: 15578127     Source Type: Journal    
DOI: 10.1089/adt.2007.086     Document Type: Review

References (23)

1. Bedner E, Li X, Gorczyca W, Melamed MR, Darzynkiewicz Z: Analysis of apoptosis by laser scanning cytometry. Cytometry 1999;35:181-195.
2. Catalano SM, McLaughlin J, Dong L, Gururaja T, Bennett M, Molineaux S, et al.: Development of a multiparameter high content screen for assaying cell cycle, proliferation and apoptosis: comparison to FACS analysis [abstract]. Clin Cancer Res 2001;7(11 Suppl):49.
3. Catalano SM, McLaughlin J, Bennett M, Molineaux S, Payan D: Development of a multiparameter digital imaging-based screen for assaying cell cycle, proliferation and apoptosis [abstract]. Presented at the American Society for Cell Biology Meeting, 2002.
4. Catalano SM, McLaughlin J, Dong L, Gururaja T, Bennett M, Molineaux S, et al.: Development of a multiparameter digital imaging-based screen for assaying cell cycle, proliferation and apoptosis: comparison to FACS analysis [abstract]. Cytometry ISAC Proceed Suppl 2002;11:177.
5. Celis M, Dennis JE, Tapia RA: A trust region strategy for nonlinear equality constrained optimization. In: Numerical Optimization 1994 (Boggs P, Byrd R, Schnabel R, eds.), pp. 71-82. SIAM, Philadelphia, 1985.
6. Cleveland WS: Robust locally weighted regression and smoothing scatterplots. J Am Stat Assoc 1979;74:829-836.
7. Zhang JH, Chung TD, Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999;4:67-73.
8. Beucher S, Meyer F: The morphological approach to segmentation: the watershed transformation. In: Optical Science and Engineering: Mathematical Morphology in Image Processing (Dougherty ER, ed.), pp. 433-481. CRC Press, Boca Raton, FL, 1992.
9. Humbert C, Giroud F, Brugal G: Detection of S cells and evaluation of DNA denaturation protocols by image cytometry of fluorescent BrdUrd labeling. Cytometry 1990;11:481-489.
10. O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, et al.: Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 1997;57:4285-4300.
11. O'Connor PM, Kohn KW: A fundamental role for cell cycle regulation in the chemosensitivity of cancer cells? Semin Cancer Biol 1992;3:409-416.
12. Majno G, Joris I: Apoptosis, oncosis, and necrosis. An overview of cell death. Am J Pathol 1995;146:3-16.
13. Darzynkiewicz Z, Crissman H, Jacobberger JW: Cytometry of the cell cycle: cycling through history. Cytometry A 2004;58:21-32.
14. Darzynkiewicz Z, Huang X, Okafuji M: Detection of DNA strand breaks by flow and laser scanning cytometry in studies of apoptosis and cell proliferation (DNA replication). Methods Mol Biol 2006;314:81-93.
15. Shoemaker RH: The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 2006;6:813-823.
16. Titus S, Neumann S, Zheng W, Southall N, Michael S, Klumpp C, et al.: Quantitative high-throughput screening using a live-cell cAMP assay identifies small-molecule agonists of the TSH receptor. J Biomol Screen 2008;13:120-127.
17. Zhu PJ, Zheng W, Auld DS, Jadhav A, Macarthur R, Olson KR, et al.: A miniaturized glucocorticoid receptor translocation assay using enzymatic fragment complementation evaluated with qHTS. Comb Chem High Throughput Screen 2008;11:545-559.
18. Eadie WT, Drijard D, James FE, Roos M, Sadoulet B: Statistical Methods in Experimental Physics. North-Holland, Amsterdam, 1971, pp. 269-271.
19. Berkova N, Lair-Fulleringer S, Féménia F, Huet D, Wagner MC, Gorna K, et al.: Aspergillus fumigatus conidia inhibit tumour necrosis factor- or staurosporine- induced apoptosis in epithelial cells. Int Immunol 2006;18:139-150.
20. Cummings BS, Kinsey GR, Bolchoz LJ, Schnellmann RG: Identification of caspase-independent apoptosis in epithelial and cancer cells. J Pharmacol Exp Ther 2004;310:126-134.
21. Park SY, Seol DW: Regulation of Akt by EGF-R inhibitors, a possible mechanism of EGF-R inhibitor-enhanced TRAIL-induced apoptosis. Biochem Biophys Res Commun 2002;295:515-518.
22. Huang R, Wallqvist A, Covell DG: Assessment of in vitro and in vivo activities in the National Cancer Institute's anticancer screen with respect to chemical structure, target specificity, and mechanism of action. J Med Chem 2006;49:1964-1979.
23. Johnson JI, Decker S, Zaharevitz D, Rubinstein LV, Venditti JM, Schepartz S, et al.: Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 2001;84:1424-1431.